Understanding Adenocarcinoma of Endometrium (Endometrial Cancer, Uterine Cancer) diagnosis? Find clear information on Endometrial Cancer staging, ICD-10 codes for Uterine Cancer, SNOMED CT codes for Adenocarcinoma of Endometrium, and healthcare documentation best practices for Adenocarcinoma of the Endometrium. This resource supports accurate clinical documentation and medical coding for optimal patient care.
Also known as
Malignant neoplasm of corpus uteri
Cancer specifically affecting the body of the uterus.
Malignant neoplasm of uterus
Cancer affecting any part of the uterus, including the cervix.
Neoplasms
Abnormal tissue growth, both benign and malignant.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the adenocarcinoma of the endometrium primary?
When to use each related code
| Description |
|---|
| Cancer of the uterine lining. |
| Precancerous changes in the uterine lining. |
| Benign smooth muscle tumor of the uterus. |
Incorrect coding of adenocarcinoma subtypes or differentiation (e.g., endometrioid, serous) impacting staging and treatment.
Inaccurate documentation of myometrial invasion depth affecting stage and subsequent treatment planning.
Missing documentation specifying laterality (if applicable) for bilateral or unilateral involvement, impacting staging.
Q: What are the most effective current treatment strategies for stage III endometrial adenocarcinoma, considering molecular classification?
A: Treatment for stage III endometrial adenocarcinoma is complex and requires a multidisciplinary approach tailored to the individual patient's molecular classification. Current National Comprehensive Cancer Network (NCCN) guidelines recommend surgery (total hysterectomy, bilateral salpingo-oophorectomy, and pelvic and para-aortic lymphadenectomy) as the cornerstone of treatment for most patients. Adjuvant therapy is frequently indicated and determined by molecular subtype, stage, and grade. For example, patients with high-risk features (e.g., serous or clear cell histology, lymphovascular space invasion) or advanced stage often benefit from adjuvant chemotherapy with carboplatin and paclitaxel. Molecular profiling, including assessment of mismatch repair (MMR) status, p53, and POLE mutation status, is essential for guiding treatment decisions. Patients with MMR-deficient tumors may benefit from immunotherapy with pembrolizumab. Consider implementing molecular testing into your clinical practice to personalize treatment strategies for optimal outcomes. Explore how S10.AI can help streamline molecular testing workflows and provide insights for personalized cancer care.
Q: How can I accurately differentiate between type I and type II endometrial adenocarcinoma in my clinical practice, and what are the key implications for prognosis and management?
A: Distinguishing between type I and type II endometrial adenocarcinoma is crucial for appropriate management. Type I, typically endometrioid histology, is associated with estrogen excess, often arises from atypical endometrial hyperplasia, and generally has a favorable prognosis. Conversely, type II tumors, including serous, clear cell, and undifferentiated carcinomas, are less common, are not associated with estrogen, and tend to be more aggressive with a poorer prognosis. Histopathological evaluation remains the gold standard for diagnosis, but certain clinical features can raise suspicion. Type I tumors often present with postmenopausal bleeding and are associated with obesity and diabetes. Type II tumors may present with abnormal vaginal discharge or pelvic pain and are less strongly associated with these risk factors. Accurate diagnosis relies on careful histopathological review, including immunohistochemistry. Given the differences in prognosis and treatment, ensuring accurate subtyping is crucial for personalized management. Learn more about how S10.AI can assist in clinical decision support for endometrial cancer by providing evidence-based insights.
Patient presents with complaints consistent with possible endometrial adenocarcinoma, including abnormal uterine bleeding, postmenopausal bleeding, and pelvic pain. A comprehensive review of systems was conducted, noting relevant symptoms such as fatigue, weight loss, and abdominal bloating. Past medical history includes hypertension and obesity. Family history is significant for breast cancer in her mother. Physical examination revealed an enlarged uterus. Transvaginal ultrasound demonstrates endometrial thickening, prompting further evaluation. Endometrial biopsy was performed and pathology report confirms the diagnosis of adenocarcinoma of the endometrium, also referred to as uterine cancer. Differential diagnoses considered included endometrial hyperplasia, uterine fibroids, and endometrial polyps. Staging workup, including pelvic MRI and CT scan of the abdomen and pelvis, is planned to assess for metastatic disease. The patient was counseled regarding treatment options for endometrial cancer, including hysterectomy, radiation therapy, chemotherapy, and hormone therapy. Risks and benefits of each treatment modality were discussed. The patient will be referred to a gynecologic oncologist for further management and treatment planning. This case of endometrial carcinoma requires careful consideration of the patient's age, overall health, and the stage of the cancer to determine the most appropriate course of action. Follow-up appointments are scheduled for ongoing monitoring and surveillance. ICD-10 code C54.1 is recorded for malignant neoplasm of corpus uteri.